BIOMEA FUSION INC. - COMMON STOCK

Biomea Fusion Announces BMF-219 in Diabetes Placed on Clinical Hold

06 يونيو 2024 16:05:53 بحسب Nasdaq GlobeNewswire

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

03 يونيو 2024 16:05:29 بحسب Nasdaq GlobeNewswire

Biomea Fusion Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 Diabetes

30 مايو 2024 09:12:39 بحسب Nasdaq GlobeNewswire

Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights

02 مايو 2024 16:05:01 بحسب Nasdaq GlobeNewswire

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

01 مايو 2024 16:10:28 بحسب Nasdaq GlobeNewswire

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

01 أبريل 2024 16:10:59 بحسب Nasdaq GlobeNewswire

Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219

01 أبريل 2024 09:02:04 بحسب Nasdaq GlobeNewswire

Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights

01 أبريل 2024 09:00:11 بحسب Nasdaq GlobeNewswire

Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function

06 مارس 2024 03:04:51 بحسب Nasdaq GlobeNewswire

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

01 مارس 2024 16:16:34 بحسب Nasdaq GlobeNewswire

Biomea Fusion Highlights Recent Updates and Anticipated 2024 Corporate Milestones at 42nd Annual J.P. Morgan Healthcare Conference

09 يناير 2024 11:02:26 بحسب Nasdaq GlobeNewswire

Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase II Study (COVALENT-112) with BMF-219

08 يناير 2024 09:00:26 بحسب Nasdaq GlobeNewswire

Biomea Fusion to Present at the 42nd Annual J.P. Morgan Healthcare Conference

02 يناير 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Biomea Fusion Presents Achievement of Minimal Residual Disease Negativity (MRD-neg) in First Complete Responder from Ongoing Phase I Study (COVALENT-101) of BMF-219 in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) at the 2023 ASH Annual Meeting

11 ديسمبر 2023 09:25:04 بحسب Nasdaq GlobeNewswire

Biomea Fusion Announces Near Doubling the Percentage of Patients with Durable HbA1c Reduction in the 200 mg Dose Cohorts

09 ديسمبر 2023 17:30:16 بحسب Nasdaq GlobeNewswire

Biomea Fusion Presents Long-Term Follow-Up Data Showing Improved Glycemic Control after 22 Weeks Off Treatment in Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes in a Poster Presentation at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

08 ديسمبر 2023 09:00:00 بحسب Nasdaq GlobeNewswire

Biomea Fusion to Present Long-Term Follow-Up Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes and Results from Ex-Vivo Human Islet Experiments at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

07 ديسمبر 2023 09:15:10 بحسب Nasdaq GlobeNewswire

Biomea Fusion Announces Health Canada Clearance of Clinical Trial Application (CTA) for BMF-219 in Type 1 Diabetes

05 ديسمبر 2023 08:30:23 بحسب Nasdaq GlobeNewswire

Biomea Fusion Announces Acceptance of Three Abstracts for its Novel Menin Inhibitor Highlighting Durable Glycemic Control in Diabetes Patients at the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in 2024

27 نوفمبر 2023 08:30:27 بحسب Nasdaq GlobeNewswire

Biomea Fusion Abstract “BMF-219: A Novel Therapeutic Agent to Reestablish Functional Beta Cells and Provide Long-term Glycemic Control" Selected as One of Six Oral Presentations at 21st World Congress Insulin Resistance, Diabetes & Cardiovascular Disease

16 نوفمبر 2023 08:30:59 بحسب Nasdaq GlobeNewswire